Trial Profile
A study of patient preference between ODM-201 and Enzalutamide in men with metastatic castrate-resistant prostate cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Feb 2023
Price :
$35
*
At a glance
- Drugs Darolutamide (Primary) ; Enzalutamide
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms ODENZA; ODENZA Preference
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 23 Feb 2021 Status changed from recruiting to active, no longer recruiting.
- 16 Feb 2019 Trial design presented at the 2019 Genitourinary Cancers Symposium